Schwarz releases "positive" data on epilepsy drug
5 December 2006 00:00 in Pharmaceutical Company Product News
Schwarz Pharma has released data from phase III clinical trials investigating the safety and efficacy of the orally administered lacosaimide used as an adjunctive therapy in epilepsy patients with uncontrolled partial seizures.
The company gave an oral presentation of the results of the trial that showed significant improvements as a result of administration of the new compound in patients with uncontrolled seizures that are currently being treated with one-to-three antiepileptic drugs.
Iris Loew-Friedrich, member of executive board of Schwarz Pharma, said that the company was "delighted" that the results had shown the efficacy of the compound in a patient group that is very hard to treat.
"Lacosamide is a promising new compound with a novel mode of action and it has the potential to play an important role in the management of epilepsy," she said.
She added that the results of this trial would be submitted to US and EU regulators to form part of the evidence for marketing authorisation for the compounds as a treatment for epilepsy patients suffering partial seizures.
Last month, Schwarz Pharma announced the identification of a dual mode of action for lacosamide, the first being related to the immediate effects in patients with epilepsy and as a diabetic neuropathic pain therapy and the second associated with potential disease-modifying effects.
Other news stories from 05/12/2006
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency